Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents

Journal of Physiology

Volumn 554, Issue 2, 2004, Pages 519-528

  Fizanne, Lionel ^a   Sigaudo Roussel, Dominique ^a   Saumet, Jean Louis ^a   Fromy, Bérengère ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VASODILATOR AGENT; CALCITONIN GENE RELATED PEPTIDE; HORMONE ANTAGONIST; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE ANTAGONIST;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BLOCKING; RODENT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL TISSUE; BINDING AFFINITY; ENDOTHELIUM; HEMODYNAMICS; PRESSURE; PRESSURE INDUCED VASODILATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SKIN; SKIN TEMPERATURE; VASCULAR CAPACITY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PEPTIDE FRAGMENTS; PRESSURE; RATS; RATS, WISTAR; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION;

EID: 0842301570     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2003.053835     Document Type: Article

References (44)

1. Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N & Payan D (1996). Skin-nervous system interactions. J Invest Dermatol 106,198-204.
2. Anzai M, Suzuki Y, Takayasu M, Kajita Y, Mori Y, Seki Y, Saito K & Shibuya M (1995). Vasorelaxant effect of PACAP-27 on canine cerebral arteries and rat intracerebral arterioles. Eur J Pharmacol 285, 173-179.
3. Arimura A & Shioda S (1995). Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16, 53-88.
4. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH & Kitada C (1991). Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129, 2787-2789.
5. Cardell LO, Stjarne P, Wagstaff SJ, Agusti C & Nadel JA (1997). PACAP-induced plasma extravasation in rat skin. Regul Pept 71, 67-71.
6. Dickinson T & Fleetwood-Walker SM (1999). VIP and PACAP: very important in pain? Trends Pharmacol Sci 20, 324-329.
7. Dickinson T, Fleetwood-Walker SM, Mitchell R & Lutz EM (1997). Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31, 175-185.
8. Dickinson T, Mitchell R, Robberecht P & Fleetwood-Walker SM (1999). The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 38, 167-180.
9. Dorner GT, Wolzt M, Eichler HG & Schmetterer L (1998). Effect of pituitary adenylate cyclase activating polypeptide 1-27 on ocular, cerebral and skin blood flow in humans. Naunyn Schmiedebergs Arch Pharmacol 358, 657-662.
10. Elsas T & White LR (1997). Evidence for a possible synergism between pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide in porcine ophthalmic artery. Acta Ophthalmol Scand 75, 159-161.
11. Fahrenkrug J, Hannibal J, Tams J & Georg B (2000). Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 20, 1205-1214.
12. Fischer TC, Hartmann P, Loser C, Springer J, Peiser C, Dinh QT, Fischer A & Groneberg DA (200 1). Abundant expression of vasoactive intestinal polypeptide receptor VPAC2 mRNA in human skin. J Invest Dermatol 117, 754-756.
13. Fizanne L, Fromy B, Preckel MP, Sigaudo-Roussel D & Saumet JL (2003). The effect of isoflurane on the skin pressure-induced vasodilation. J Vasc Res 40, 416-422.
14. Fromy B, Abraham P & Saumet JL (1998). Non-nociceptive capsaicin-sensitive nerve terminal stimulation allows for an original vasodilatory reflex in the human skin. Brain Res 811, 166-168.
15. Fromy B, Abraham P & Saumet JL (2000a). Progressive calibrated pressure device to measure cutaneous blood flow changes to external pressure strain. Brain Res Protoc 5, 198-203.
16. Fromy B, Merzeau S, Abraham P & Saumet JL (2000b). Mechanisms of the cutaneous vasodilator response to local external pressure application in rats: Involvement of CGRP, neurokinins, Prostaglandins and. Br J Pharmacol 131, 1161-1171.
17. Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M & Robberecht P (1997). In vitro Properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18, 1555-1560.
18. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA & Waschek JA (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50, 265-270.
19. Laburthe M, Couvineau A & Marie JC (2002). VPAC receptors for VIP and PACAP. Receptors Channels 8, 137-153.
20. Lai CC, Wu SY, Lin HH & Dun NJ (1997). Excitatory action of pituitary adenylate cyclase activating polypeptide on rat sympathetic preganglionic neurons in vivo and in vitro. Brain Res 748, 189-194.
21. Lioudyno M, Skoglosa Y, Takei N & Lindholm D (1998). Pituitary adenylate cyclase-activating polypeptide (PACAP) protects dorsal root ganglion neurons from death and induces calcitonin gene-related peptide (CGRP) immunoreactivity in vitro. J Neurosci Res 51, 243-256.
22. Lundeberg L & Nordlind K (1999). Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study. Arch Dermatol Res 291, 201-206.
23. May V, Beaudet MM, Parsons RL, Hardwick JC, Gauthier EA, Durda JP & Braas KM (1998). Mechanisms of pituitary adenylate cyclase activating polypeptide (PACAP)-induced depolarization of sympathetic superior cervical ganglion (SCG) neurons. Ann N Y Acad Sci 865, 164-175.
24. Miyata A, Sato K, Hino J, Tamakawa H, Matsuo H & Kangawa K (1998). Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor. Ann N Y Acad Sci 865, 73-81.
25. Moller K, Zhang YZ, Hakanson R, Luts A, Sjolund B, Uddman R & Sundler F (1993). Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57, 725-732.
26. Moro O & Lerner EA (1997). Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 272, 966-970.
27. Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA & Tajima M (1999). Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem 274, 23103-23110.
28. Morris SJ & Shore AC (1996). Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. J Physiol 496, 531-542.
29. Mulder H, Uddman R, Moller K, Zhang YZ, Ekblad E, Alumets J & Sundler F (1994). Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63, 307-312.
30. 17] VIP. Am J Physiol 250, G553-G557.
31. Rekik M, Delvaux M, Frexinos J & Bueno L (1998). Role of vasoactive intestinal polypeptide in the adaptation of intestinal smooth muscle cells to mechanical distension. J Pharmacol Exp Ther 287, 832-838.
32. Reubi JC (2000). In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci 921, 1-25.
33. Saumet JL, Dittmar A & Leftheriotis G (1986). Non-invasive measurement of skin blood flow: comparison between plethysmography, laser-Doppler flowmeter and heat thermal clearance method. Int J Microcirc Clin Exp 5, 73-83.
34. Seebeck J, Lowe M, Kruse ML, Schmidt WE, Mehdorn HM, Ziegler A & Hempelmann RG (2002). The vasorelaxant effect of pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in isolated rat basilar arteries is partially mediated by activation of nitrergic neurons. Regul Pept 107, 115-123.
35. Sloan JB & Soltani K (1986). Iontophoresis in dermatology. A review. J Am Acad Dermatol 15, 671-684.
36. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H & Schmidt WE (1999). Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP-38 is increased in patients with psoriasis. Regul Pept 80, 49-55.
37. + influx-dependent membrane depolarization in bovine adrenal chromaffin cells. Endocrinology 137, 956-966.
38. Tatsuno I, Yada T, Vigh S, Hidaka H & Arimura A (1992). Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide increase cytosolic free calcium concentration in cultured rat hippocampal neurons. Endocrinology 131, 73-81.
39. Uchida D, Tatsuno I, Tanaka T, Hirai A, Saito Y, Moro O & Tajima M (1998). Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. Ann N Y Acad Sci 865, 253-258.
40. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A & Vaudry H (2000). Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52, 269-324.
41. Wallengren J (1997). Vasoactive peptides in the skin. J Invest Dermatol Symp Proceedings 2, 49-55.
42. Warren JB, Larkin SW, Coughlan M, Kajekar R & Williams TJ (1992). Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol 106, 331-334.
43. Wilson AJ & Warren JB (1993). Adenylate cyclase-mediated vascular responses of rabbit aorta, mesenteric artery and skin microcirculation. Br J Pharmacol 110, 633-638.
44. Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ & Kikuyama S (2002). PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci 3, 423-439.